Quince Therapeutics QNCX · USD

Its shares trade under the ticker QNCX. It has been listed since 9 May 2019.

Cortexyme, Inc. is a biopharmaceutical company, which develops therapeutics based on data supporting a new theory of the cause of Alzheimer's and other neurodegenerative disorders. The company is headquartered in South San Francisco, California. The company went IPO on 2019-05-09. The firm is focused on providing disease-modifying therapeutics to treat Alzheimer’s and other degenerative diseases. The firm is focused on a infectious pathogen tied to neurodegeneration in humans and animal models. The Company’s lead drug candidate, COR388, is an orally-administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer’s disease. COR388 is designed to target an upstream driver of multiple Alzheimer’s pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. David LamondIndependent Chairman of the Board$93,640
• Dr. Charles RyanPresident$893,050
• Dr. Dirk ThyeChief Executive Officer, Chief Medical Officer, Director, since 2022$2.7m
• Mr. Brendan HannahChief Operating Officer, Chief Compliance Officer, Chief Business Officer$1.4m
• Dr. Una RyanLead Independent Director$86,140
• Dr. Luca BenattiIndependent Director$60,140
• Ms. June BrayIndependent Director$67,640
• Dr. Margaret McloughlinIndependent Director$69,640
• Dr. Rajiv PatniIndependent Director$115,895
• Mr. Christopher SennerIndependent Director$75,140

Overall

54

Environment

56

Social

68

Governance

37

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.